Results 191 to 200 of about 116,902 (309)

Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review. [PDF]

Front Oncol
Dima G, Di Nunno V, Aprile M, Gatto L, Tosoni A, Argento CM, Margotti M, Bartolini S, Franceschi E.   +8 more
europepmc   +1 more source

RTA-408 induces JNK-dependent apoptosis and autophagy in breast cancer cells. [PDF]

Oncol Lett
Chen YJ, Tsai HP, Chen MY, Chen IH, Chen WC, Tseng TT, Wang CY, Lee JH.   +7 more
europepmc   +1 more source

Of mice and men—The emerging oral–gut–brain axis of health and disease

Periodontology 2000, EarlyView.
Abstract Objectives Oral health's inextricable links to systemic health are highlighted by the emerging oral–gut–brain axis and other well‐known axes. There is growing evidence of a complex oral–gut–brain axis linking mouth and gut microbiomes with the central nervous system.
Yvonne L. Hernandez‐Kapila, Daniel J. Weisenberger   +1 more
wiley   +1 more source

The effect of PARP inhibitor-based targeted therapy on BRCA-mutated ovarian cancer: systematic literature review. [PDF]

Front Oncol
Panjarwanto DA, Nabila P, Octavia L, Indrawan IWA, Utomo RP, Permana AY, Kaspan, Adnyana IGHE, Javier RM, Akbar MZH.   +9 more
europepmc   +1 more source

Hyperthermia‐induced cytotoxicity and modulation of PD‐L1 and MHC‐I expression in human non‐small cell lung cancer cell lines

Experimental Physiology, EarlyView.
Abstract Hyperthermia has recently been applied to treat human non‐small cell lung cancer (NSCLC). However, the mechanisms underlying cytotoxic sensitivity of NSCLC cells to hyperthermia are not fully understood. In this study, five NSCLC cell lines with different epidermal growth factor receptor (EGFR), Kirsten rat sarcoma and tumor protein p53 ...
Yun‐Chieh Tu, Wei‐Chen Yeh, Yi‐Wei Fang, Ko‐Hsuan Lo, Lei‐Ni Liang, Xu‐Chen Liu, Chia‐Chi Tsai, Chih‐Cheng Cheng, Meng‐Chieh Lin, Hsin‐Hsien Yu, Bor‐Chyuan Su   +10 more
wiley   +1 more source

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors. [PDF]

RSC Adv
Rani D, Plebanski M, Chatterjee T.
europepmc   +1 more source

Olaparib‐associated cutaneous vasculitis in a patient with breast cancer

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marcial Álvarez‐Salafranca, Teresa Puértolas, Adrián Diago, María Carmen Gómez‐Mateo   +3 more
wiley   +1 more source

VEGF inhibitor‐induced vascular dysfunction involves redox‐sensitive PARP activation and SIRT1 disruption

Experimental Physiology, EarlyView.
Abstract Vascular endothelial growth factor receptor (VEGFR) inhibitors are effective antiangiogenic agents used in cancer therapy. However, they are associated with cardiovascular disease, including hypertension and vascular dysfunction. The molecular mechanisms underlying these cardiovascular toxicities are unclear, but oxidative stress might be ...
Karla B. Neves, Rheure Alves‐Lopes, Augusto C. Montezano, Rhian M. Touyz   +3 more
wiley   +1 more source

Advances in Phase III Clinical Trials and Future Challenges of Targeted Therapy in Advanced Ovarian Cancer. [PDF]

Cancer Manag Res
Zhang L, Qiao R, Chen M, Yang Z, Gong M, Yu R.   +5 more
europepmc   +1 more source

Nanomaterial‐Mediated Radiotherapy–Immunotherapy Combinations: Breaking Immunosuppression and Revolutionizing Cancer Treatment

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Nanomaterials integrate radiotherapy and immunotherapy by enhancing radiosensitivity, remodeling the immunosuppressive tumor microenvironment, and promoting systemic antitumor immunity. This review summarizes the latest strategies of nanomaterial‐mediated combinations (RT, immunotherapy, IRT) and highlights future directions for overcoming clinical ...
Peijie Li, Xiangqin Wang, Sisi He, Hu Ma
wiley   +1 more source